Intensity Therapeutics Executes 1-for-25 Reverse Stock Split to Meet Nasdaq Listing Requirements
Event summary
- Intensity Therapeutics approved a 1-for-25 reverse stock split, effective February 18, 2026, to comply with Nasdaq's minimum bid price requirement.
- The split reduces outstanding shares from ~63.3 million to ~2.5 million, with trading on a split-adjusted basis beginning February 19, 2026.
- INT230-6, the company's lead cancer therapy, remains in Phase 3 trials for soft tissue sarcoma and Phase 2 for triple-negative breast cancer.
- The reverse split was approved by stockholders on October 22, 2025, and is intended to boost the per-share trading price.
The big picture
Intensity Therapeutics' reverse stock split is a defensive move to avoid delisting, reflecting broader challenges faced by late-stage biotech companies with low stock prices. The company's focus on intratumoral cancer therapies positions it in a competitive oncology space, but its ability to execute clinical trials and secure funding will determine long-term viability. The split reduces share count but does not address underlying financial pressures.
What we're watching
- Market Reaction
- How investors will respond to the reverse split and whether it stabilizes the stock price above Nasdaq's $1 minimum threshold.
- Clinical Progress
- The pace at which INT230-6 advances through Phase 3 trials and its potential impact on regulatory approval timelines.
- Financial Health
- Whether the reverse split buys Intensity Therapeutics enough time to secure additional funding or achieve milestones to sustain operations.
Related topics